reduced intensity conditionings
Drugcomparison of non myeloablative (Flu-TBI) and reduced intensity (FLU-BU-ATG)
NCT Number: NCT00894049
This study is a prospective comparison between 2 popular regimens based on reduced intensity or non-myeloablative approaches to define the optimal myeloablative and/or immu-nonsuppressive association for reduced intensity conditionings (RIC).
Flu-Bu-ATG (Study A) associated Fludarabine (30mg/m²/5 days), Oral Busulfan (8 mg/kg over 2 days) and Thymoglobuline (2.5 mg/m²/1day).
Flu-TBI (Study B) consisted of Fludarabine (25mg/m²/ 3 days) and 2 Gy total body irradiation (TBI).
A randomization of 2 phase study according to the methodology developed by Liu et al (Liu, 1993 and 2001) for the evaluation of multiple innovative approaches.
Primary endpoint is one year overall survival (OS). Stopping rules included excessive engraftment failure and trans-plant related mortality ratio. Data are yearly reviewed by an independent safety review board (ISRB).
Inclusion criteria are patients presenting a hematological malignancy, eligible for non myeloablative allo stem cell transplantation (SCT), aged between 18 and 65, with a suitable HLA identical sibling. All patients and donors are included after giving written informed consent.
Protocol was submitted and accepted by the ethical committee and the AFFSSAPS cellular therapies committee (national agency).
Looking for future studies?
Notify Me18 year–65 year
All sexes
Interventional
Phase 2
CHU, Bordeaux Pessac, France
Healthy volunteers accepted: No
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
comparison of non myeloablative (Flu-TBI) and reduced intensity (FLU-BU-ATG)
Time frame: one year
Institut Paoli-Calmettes
Other
A Multicenter Prospective Randomized Study Comparing Non Myeloablative (Flu-TBI) and Reduced Intensity (FLU-BU-ATG) Conditioning in Allogenic Transplantation
Acronym: ITAC02-01
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT00876148
Allograft, Blood-Borne Infections
Torino, Italy
View Trial DetailsNCT07565558
Allograft, Alveolar Ridge Preservation
Bytom, Silesian Voivodeship, Poland
View Trial DetailsNCT02882828
Allograft
Amiens, France
View Trial DetailsNCT07210541
Allograft, Bioprosthesis Failure
View Trial Details